Clinical Trial Update: Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial investigating D-cycloserine with imagery rescripting for subclinical PTSD has been withdrawn after Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• D-cycloserine (D-cycloserine)

Snippet

Sponsor: Boston University Charles River Campus | Conditions: PTSD | Phase 2, Phase 3 | Status: WITHDRAWN